Invest in Transformative Ideas

The Autism Eyes™ platform accelerates the time to diagnosis for children with autism, and drives clinical workflow efficiency, by providing a rapid, objective assessment of autism risk. Current diagnostic processes are subjective and lengthy, resulting in patient backlogs of up to twelve months. Well-established research indicates that earlier ASD diagnosis leads to improved outcomes. Autism Eyes addresses a clear unmet need by streamlining clinical workflow to enable earlier diagnosis, earlier treatment access, and in turn, improved outcomes.

Avaneer Health was founded by leaders with the vision to transform how healthcare shares information via a unique, interoperable network designed by and for healthcare. Avaneer streamlines healthcare administration where health information can be shared in real-time, with permission, and in control of the owner or steward of the data, leveraging collaboration services for identity, workflow, zero trust security, and solution marketplace.

Bering Health is a digital health start-up that will provide virtual care for low-acuity and low-complexity medical conditions. Individuals will be able to utilize the Company’s digital platform in a convenient setting, such as at home, yet it will still be integrated with an individual’s local provider, thereby maintaining continuous care and up-to-date medical records.

Ceraxis Health has developed a platform for longitudinal tracking of symptoms and management to address patient functional health, quality of life outcomes and treatment planning and monitoring through real-time, data-driven care management for neurological conditions such as Parkinson’s Disease.

Qr8 Health is a digital health company providing standardized, validated, patient-self-administered assessments for the measurement of neurological and motor function along with patient-reported outcomes administered on a mobile tablet device and easily integrated into electronic health records. Founded in 2016, the company has developed applications enabling transformational improvement in patient care by providing medical solutions for collecting highly standardized clinical data and patient-reported outcomes, in any medical or home setting.

Xealth is a digital health prescribing platform that enables clinicians to easily integrate, prescribe, and monitor digital health tools for patients from their EHR workflows.

Cardionomic is developing a neuromodulation device for the management of acute decompensated heart failure (ADHF) by improving cardiac output via improved contractility. The inpatient cost of ADHF care is extremely high – accounting for 60% of total heart failure expenditures.

Centerline’s Intra-Operative Positioning System (IOPS) is a platform technology that enhances visualization and navigation across a range of endovascular procedures, while reducing exposure to harmful radiation for patients and physicians.

Enspire DBS Therapy aims to revitalize stroke recovery using deep brain stimulation alongside physical rehabilitation to restore motor function for stroke survivors living with disability.

Infuseon Therapeutics, founded in 2012, enables reliable delivery of therapeutics to the brain via a proprietary multiport convection-enhanced delivery catheter, designed by a Cleveland Clinic neurosurgeon to more effectively deliver life-saving drugs to patients at the site of disease.

MediView is empowering clinicians with “X-Ray Vision” digitally assisted surgery powered by augmented reality, telepresence, and data-driven insights. By simplifying procedures with this “X-Ray Vision”, healthcare delivery can be simplified, democratized, and informed.

Method AI's image-guided navigation platform is designed to enable improved outcomes and enhance robotic surgical procedures, initially impacting patients’ surgical oncology journey.

Mitria Medical is developing a minimally invasive transcatheter mitral valve repair implant.

NaviGate Cardiac Structures Inc. (NCSI) is developing transcatheter tricuspid valve replacement solution for the treatment of tricuspid regurgitation.

Perfusion Solutions is developing a minimally-invasive implantable ultra-small heart pump technology for acute and chronic heart failure.

XII Medical is developing a minimally-invasive outpatient technology for the treatment of obstructive sleep apnea (OSA).

Abcon Therapeutics is developing an antibody-drug conjugate (ADC) that targets the CD6 cell surface protein on T-cells. In pathogenic conditions, such as T-cell lymphoma and inflammatory conditions, the ADC binds to all T-cells, but the drug (toxin) only affects activated dividing T-cells (i.e. the cancerous ones in T-Cell Lymphoma) so these are killed, and normal inactive T-cells are spared. CD6 is found exclusively on T-cells; thus, the ADC specificity is very good. The Company plans to develop a pipeline of ADCs targeting different types of cancer.

Cleveland Diagnostics is a biotechnology company with proprietary first-in-class technology and reagents to enable development of high efficacy and affordable tests, focused on early detection and diagnostics of cancer and neurodegenerative diseases.

Mobius is personalizing Inflammatory Bowel Disease (IBD) therapeutic and diagnostic care, through its proprietary AI tool, applied to targeting host and microbiome pathways that infect gastrointestinal (GI) tract wounds. The Company’s technology can also identify subsets of patients who are likely to respond favorably to an existing arsenal of well-characterized drug candidates. Additionally, Mobius is developing therapeutics to treat the dysfunctional wound healing and dysfunctional microbiome associated with IBD.

NeuroTherapia is a clinical stage biotechnology company developing novel therapies that decrease the neuroinflammation associated with diseases such as neuropathic pain and Alzheimer’s disease.

Zehna Therapeutics is an early-stage biotech company focused on developing novel, non-bacteriocidal inhibitors of selected gut microbial pathways clinically and mechanistically linked with chronic metabolic diseases such as Chronic Kidney Disease and cardiovascular disease. The Company’s lead compounds inhibit the gut microbial enzyme CutC, preventing the conversion of dietary choline to trimethylamine (TMA) and subsequently to trimethylamine N-oxide (TMAO). Increased levels of TMAO, metabolized and secreted by gut bacteria, in the host results in a dose-dependent increase in poor outcomes in clinical studies and animal models.